Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Revlimid lenalidomide: Phase I/II data

In an ongoing Phase I/II trial, 7 of 10 patients achieved responses after treatment with

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE